Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

Mario Giuliano, Antonio Giordano, Summer Jackson, Ugo De Giorgi, Michal Mego, Evan N. Cohen, Hui Gao, Simone Anfossi, Beverly C. Handy, Naoto T. Ueno, Ricardo H. Alvarez, Sabino De Placido, Vicente Valero, Gabriel N. Hortobagyi, James M. Reuben, Massimo Cristofanilli

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination. Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher's exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test. Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with

Original languageEnglish
Article number440
JournalBreast Cancer Research
Volume16
Issue number5
DOIs
Publication statusPublished - Sep 16 2014

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Cell Count
Treatment Failure
Population
Retrospective Studies
Neoplasm Metastasis
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. / Giuliano, Mario; Giordano, Antonio; Jackson, Summer; De Giorgi, Ugo; Mego, Michal; Cohen, Evan N.; Gao, Hui; Anfossi, Simone; Handy, Beverly C.; Ueno, Naoto T.; Alvarez, Ricardo H.; De Placido, Sabino; Valero, Vicente; Hortobagyi, Gabriel N.; Reuben, James M.; Cristofanilli, Massimo.

In: Breast Cancer Research, Vol. 16, No. 5, 440, 16.09.2014.

Research output: Contribution to journalArticle

Giuliano, M, Giordano, A, Jackson, S, De Giorgi, U, Mego, M, Cohen, EN, Gao, H, Anfossi, S, Handy, BC, Ueno, NT, Alvarez, RH, De Placido, S, Valero, V, Hortobagyi, GN, Reuben, JM & Cristofanilli, M 2014, 'Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination', Breast Cancer Research, vol. 16, no. 5, 440. https://doi.org/10.1186/s13058-014-0440-8
Giuliano, Mario ; Giordano, Antonio ; Jackson, Summer ; De Giorgi, Ugo ; Mego, Michal ; Cohen, Evan N. ; Gao, Hui ; Anfossi, Simone ; Handy, Beverly C. ; Ueno, Naoto T. ; Alvarez, Ricardo H. ; De Placido, Sabino ; Valero, Vicente ; Hortobagyi, Gabriel N. ; Reuben, James M. ; Cristofanilli, Massimo. / Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. In: Breast Cancer Research. 2014 ; Vol. 16, No. 5.
@article{c8b2ee70d4c54aa48accba1685cd60a4,
title = "Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination",
abstract = "Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination. Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher's exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test. Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with",
author = "Mario Giuliano and Antonio Giordano and Summer Jackson and {De Giorgi}, Ugo and Michal Mego and Cohen, {Evan N.} and Hui Gao and Simone Anfossi and Handy, {Beverly C.} and Ueno, {Naoto T.} and Alvarez, {Ricardo H.} and {De Placido}, Sabino and Vicente Valero and Hortobagyi, {Gabriel N.} and Reuben, {James M.} and Massimo Cristofanilli",
year = "2014",
month = "9",
day = "16",
doi = "10.1186/s13058-014-0440-8",
language = "English",
volume = "16",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

AU - Giuliano, Mario

AU - Giordano, Antonio

AU - Jackson, Summer

AU - De Giorgi, Ugo

AU - Mego, Michal

AU - Cohen, Evan N.

AU - Gao, Hui

AU - Anfossi, Simone

AU - Handy, Beverly C.

AU - Ueno, Naoto T.

AU - Alvarez, Ricardo H.

AU - De Placido, Sabino

AU - Valero, Vicente

AU - Hortobagyi, Gabriel N.

AU - Reuben, James M.

AU - Cristofanilli, Massimo

PY - 2014/9/16

Y1 - 2014/9/16

N2 - Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination. Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher's exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test. Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with

AB - Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination. Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher's exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test. Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with

UR - http://www.scopus.com/inward/record.url?scp=84909629677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909629677&partnerID=8YFLogxK

U2 - 10.1186/s13058-014-0440-8

DO - 10.1186/s13058-014-0440-8

M3 - Article

C2 - 25223629

AN - SCOPUS:84909629677

VL - 16

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 5

M1 - 440

ER -